专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060177510A1 Dual controlled release osmotic device 有权
标题翻译：双控制释放渗透装置
公开(公告)号：US20060177510A1
公开(公告)日：2006-08-10
申请号：US11321736
申请日：2005-12-29
申请人： Juan Vergez , Marcelo Ricci
发明人： Juan Vergez , Marcelo Ricci
IPC分类号： A61K9/24
CPC分类号： A61K45/06 , A61K9/0004 , A61K9/209 , A61K31/216 , A61K2300/00
摘要： A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided. Together, oxybutynin and the second drug provide an overall improved therapeutic benefit over either agent alone when administered at approximately the same dose.
摘要翻译：提供了用奥昔布宁和第二种药物治疗失禁的药物组合物和剂型。第二种药物可以是达里芬那定或托特罗定。根据给药途径，使用的剂型和使用的第二种药物，剂型可以独立地包括治疗或亚治疗量的奥昔布宁和第二种药物。具体实施方案包括提供奥昔布宁和第二种药物的受控释放的剂型，以维持哺乳动物治疗有效量的奥昔布宁和/或第二剂在延长的时间内。提供了含有双层芯的渗透装置。渗透装置提供从核心两种药物的双重控制释放。提供了一种用药物组合物和剂型治疗尿（应激或促进）失禁的方法。当以大约相同的剂量施用时，奥昔布宁和第二种药物一起提供了比单独的药物更好的治疗益处。

2. 发明申请

US20060159763A1 Osmotic device containing amantadine and an osmotic salt 有权
标题翻译：渗透装置含有金刚烷胺和渗透盐
公开(公告)号：US20060159763A1
公开(公告)日：2006-07-20
申请号：US11287882
申请日：2005-11-28
申请人： Glenn Meyer , Ethel Feleder , Marcelo Ricci , Marcelo Coppari , Marcelo Befumo , Joaquina Faour , Juan Vergez
发明人： Glenn Meyer , Ethel Feleder , Marcelo Ricci , Marcelo Coppari , Marcelo Befumo , Joaquina Faour , Juan Vergez
IPC分类号： A61K31/13 , A61K9/24
CPC分类号： A61K9/0004
摘要： The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.
摘要翻译：本发明的渗透装置含有包含金刚烷胺和渗透盐的盐的单一核心，其中两种盐具有共同的离子。金刚烷胺的释放速率通过增加器件芯体中的渗透盐的量从一级释放曲线修改为零级，伪零级或S形释放曲线。渗透装置包括具有受控孔隙度的半透膜，其可以根据需要进行调整，以与渗透盐配合以提供预定的药物释放曲线。渗透盐不需要涂覆，并且与金刚烷胺盐混合。

3. 发明申请

US20060204578A1 Dual controlled release dosage form 有权
公开(公告)号：US20060204578A1
公开(公告)日：2006-09-14
申请号：US11355315
申请日：2006-02-15
申请人： Juan Vergez , Marcelo Ricci
发明人： Juan Vergez , Marcelo Ricci
IPC分类号： A61K31/7024 , A61K31/551 , A61K31/55 , A61K31/473 , A61K31/426 , A61K9/24 , A61K31/277
CPC分类号： A61K9/0004 , A61K9/2072 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/2886 , A61K9/4808 , A61K9/5042 , A61K9/5078 , A61K31/135 , A61K31/137 , A61K31/216 , A61K31/365 , A61K31/381 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/4025 , A61K31/4422 , A61K31/4439 , A61K31/5415 , A61K31/5517 , A61K45/06 , A61K2300/00
摘要： A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.

4. 发明申请

US20050129764A1 Osmotic device containing licofelone 审中-公开
标题翻译：渗透装置含有licofelone
公开(公告)号：US20050129764A1
公开(公告)日：2005-06-16
申请号：US10733156
申请日：2003-12-11
申请人： Juan Vergez , Joaquina Faour , Marcelo Ricci , Marcelo Befumo
发明人： Juan Vergez , Joaquina Faour , Marcelo Ricci , Marcelo Befumo
IPC分类号： A61K9/00 , A61K9/28 , A61K31/40 , A61K31/407 , A61K31/415 , A61K9/24
CPC分类号： A61K9/0004 , A61K9/2886 , A61K31/407 , A61K31/415
摘要： The present invention provides an osmotic device containing controlled release licofelone and, optionally, a rapid release licofelone in an external coat. The osmotic devices provide a controlled release of licofelone to maintain therapeutically effective levels of licofelone in plasma when administered once per day. The device is useful for the treatment of osteoarthritis, rheumatoid arthritis, and inflammatory related disorders. The present devices provide licofelone according to specific release profiles in combination with specific formulations.
摘要翻译：本发明提供含有受控释放的非香豆素和任选的外用涂层中的快速释放的licofelone的渗透装置。当每天施用一次时，渗透装置提供了用于维持血浆中治疗有效水平的licofelone的药代动力学的控制释放。该装置可用于治疗骨关节炎，类风湿性关节炎和炎性相关疾病。本发明的装置根据特定的释放特征与特定的配方组合提供了licofelone。

5. 发明申请

US20070275060A1 Extended release solid pharmaceutical composition containing carbidopa and levodopa 审中-公开
标题翻译：含有卡比多巴和左旋多巴的延长释放固体药物组合物
公开(公告)号：US20070275060A1
公开(公告)日：2007-11-29
申请号：US11498307
申请日：2006-08-02
申请人： Marcelo Befumo , Marcelo Ricci , Ethel Feleder , Glenn Meyer , Joaquina Faour , Juan Vergez
发明人： Marcelo Befumo , Marcelo Ricci , Ethel Feleder , Glenn Meyer , Joaquina Faour , Juan Vergez
IPC分类号： A61K31/137 , A61P25/16 , A61K9/24
CPC分类号： A61K9/2009 , A61K9/2054 , A61K9/209 , A61K9/2866 , A61K31/137 , A61K31/198 , A61K45/06
摘要： The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and/or levodopa. The extended release composition in the tablet excludes a release rate-controlling polymer, and a release rate-controlling coating; however, the release of the carbidopa and/or levodopa is independently optionally delayed for a lag time. The invention also provides a tablet having a extended release form of levodopa and a rapid or immediate release form of carbidopa. A tablet can contain levodopa present in extended release form and rapid or immediate release form, and carbidopa present in extended release form and rapid or immediate release form. The tablet is used to treat Parkinson's disease and other movement related disorders, diseases or syndromes.
摘要翻译：本发明提供一种压缩片剂，其提供含有延迟释放形式的卡比多巴和延长释放形式的左旋多巴的延长释放片剂。片剂任选地还包含卡比多巴和/或左旋多巴的立即或快速释放组合物。片剂中的延长释放组合物不包括释放速率控制聚合物和释放速率控制涂层; 然而，卡比多巴和/或左旋多巴的释放独立地任选延迟滞后时间。本发明还提供具有延长释放形式的左旋多巴的片剂和卡比多巴的快速或立即释放形式。片剂可以含有以延长释放形式存在的左旋多巴和快速或立即释放形式，以及以延长释放形式存在的卡比多巴和快速或即时释放形式。该片用于治疗帕金森病和其他与运动相关的疾病，疾病或综合征。

6. 发明申请

US20070077301A1 Venlafaxine osmotic device formulation 审中-公开
标题翻译：文拉法辛渗透装置制剂
公开(公告)号：US20070077301A1
公开(公告)日：2007-04-05
申请号：US11532186
申请日：2006-09-15
申请人： Glenn Meyer , Marcelo Ricci , Guido Bigatti
发明人： Glenn Meyer , Marcelo Ricci , Guido Bigatti
IPC分类号： A61K9/24 , A61K31/137
CPC分类号： A61K9/0004 , A61K9/2018 , A61K31/137
摘要： The present invention provides an osmotic device containing controlled release venlafaxine in the core, wherein the osmotic device exhibits a reduced food effect as compared to a reference controlled release capsule formulation. Some embodiments include venlafaxine in controlled release form in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of depression in Alzheimer's and/or Parkinson's patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.
摘要翻译：本发明提供一种渗透装置，其含有核心中的文拉法苦心，其中渗透装置与参考控释胶囊制剂相比表现出降低的食物效果。一些实施方案包括与快速释放外涂层中的抗阿尔茨海默氏病或抗帕金森氏病药物组合的控释药物的文拉法辛。美金刚被用作抗阿尔茨海默病药物或抗帕金森氏药物。本发明的具体实施方案提供具有预定释放特征的渗透装置。渗透装置的一个实施例包括已经被喷涂而不是被压缩涂覆到该装置上的外部涂层。该装置可用于治疗阿尔茨海默病和/或帕金森氏症患者的抑郁症。该装置和方法还可用于治疗或改善与阿尔茨海默病，帕金森病或任何其他神经障碍相关的其它症状。提供文拉法辛与美金刚的快速或立即释放相结合的受控，持续或延长释放的其它剂型在本发明中是有用的。

7. 发明申请

US20050163851A1 Osmotic device containing a venlafaxine salt and a salt having an ion in common 有权
标题翻译：渗透装置含有文拉法辛盐和具有共同离子的盐
公开(公告)号：US20050163851A1
公开(公告)日：2005-07-28
申请号：US11010829
申请日：2004-12-13
申请人： Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour , Ana Pastini , Marcelo Befumo
发明人： Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour , Ana Pastini , Marcelo Befumo
IPC分类号： A61K9/00 , A61K9/24 , A61K31/13 , A61K31/137 , A61K31/277
CPC分类号： A61K9/0004 , A61K31/13 , A61K31/137 , A61K31/277
摘要： The osmotic devices of the present invention include a single core comprising a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. The release rate of the active drug is reduced, and the release profile of the active drug is modified, from a first order release profile to a zero order, pseudo-zero order, or sigmoidal release profile, by increasing the amount of the sodium chloride in the core of the device. In one embodiment the sodium chloride is used to modify a controlled release profile to a delayed and controlled release profile.
摘要翻译：本发明的渗透装置包括包含药物和渗透盐的盐的单核心，其中药物盐和渗透盐具有共同的离子。活性药物的释放速率降低，并且通过增加氯化钠的量，将活性药物的释放曲线从一级释放曲线修改为零级，伪零级或S形释放曲线在设备的核心。在一个实施方案中，氯化钠用于将受控释放曲线修饰为延迟和控制释放曲线。

8. 发明申请

US20060063810A1 Combination treatment for impaired motor function in parkinson's disease 审中-公开
标题翻译：帕金森病运动功能受损的组合治疗
公开(公告)号：US20060063810A1
公开(公告)日：2006-03-23
申请号：US11215797
申请日：2005-08-30
申请人： Juan Vergez , Alan Lanier , Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour
发明人： Juan Vergez , Alan Lanier , Ethel Feleder , Glenn Meyer , Marcelo Ricci , Joaquina Faour
IPC分类号： A61K31/452 , A61K31/343 , A61K31/137
CPC分类号： A61K45/06 , A61K31/00 , A61K31/137 , A61K31/343 , A61K31/452 , A61K2300/00
摘要： The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and/or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.
摘要翻译：本发明提供了治疗与帕金森病相关的运动功能障碍，抗帕金森氏病药物治疗的方法及其剂型。左旋多巴治疗和/或与帕金森病有关的痴呆症。本发明包括联合施用NMDA受体拮抗剂和抗抑郁药，例如金刚烷胺和西酞普兰或文拉法辛，或NMDA受体拮抗剂和抗焦虑剂（例如金刚烷胺和丁螺环酮或曲唑酮）的组合，用于改善不期望的颤抖，运动障碍，运动障碍或与一种或多种不同疾病或疾病相关的运动迟缓。药物可以包含在单一剂型中。一个实施方案包括含有受控释放形式的每种药物的组合剂型。另一个实施方案包括提供NMDA受体拮抗剂的受控释放的组合剂型和在施用于受试者之后神经活性剂的快速释放。

9. 发明申请

US20060062851A1 Delivery device containing venlafaxine and memantine and methods of use thereof 审中-公开
标题翻译：含有文拉法辛和美金刚的递送装置及其使用方法
公开(公告)号：US20060062851A1
公开(公告)日：2006-03-23
申请号：US11159410
申请日：2005-06-22
申请人： Juan Vergez , Joaquina Faour , Marcelo Ricci , Ana Pastini
发明人： Juan Vergez , Joaquina Faour , Marcelo Ricci , Ana Pastini
IPC分类号： A61K9/24
CPC分类号： A61K45/06 , A61K9/0004 , A61K9/209
摘要： The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of depression in Alzheimer's disease and/or Parkinson's disease patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.
摘要翻译：本发明提供一种渗透装置，其包含与快速释放外涂层中的抗阿尔茨海默氏病或抗帕金森氏药物组合的核心中的文拉法而控制释放。美金刚被用作抗阿尔茨海默病药物或抗帕金森氏药物。本发明的具体实施方案提供具有预定释放特征的渗透装置。渗透装置的一个实施例包括已经被喷涂而不是被压缩涂覆到该装置上的外部涂层。该装置可用于治疗阿尔茨海默病和/或帕金森病患者的抑郁症。该装置和方法还可用于治疗或改善与阿尔茨海默病，帕金森病或任何其他神经障碍相关的其它症状。提供文拉法辛与美金刚的快速或立即释放相结合的受控，持续或延长释放的其它剂型在本发明中是有用的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式